APA

Tsuburaya A., Morita S., Kodera Y., Kobayashi M., Shitara K., Yamaguchi K., Yoshikawa T., Yoshida K., Yoshino S. & Sakamoto J. (20130617). A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). : BMC cancer.

Chicago

Tsuburaya Akira, Morita Satoshi, Kodera Yasuhiro, Kobayashi Michiya, Shitara Kohei, Yamaguchi Kensei, Yoshikawa Takaki, Yoshida Kazuhiro, Yoshino Shigefumi and Sakamoto Jun-ichi. 20130617. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). : BMC cancer.

Harvard

Tsuburaya A., Morita S., Kodera Y., Kobayashi M., Shitara K., Yamaguchi K., Yoshikawa T., Yoshida K., Yoshino S. and Sakamoto J. (20130617). A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). : BMC cancer.

MLA

Tsuburaya Akira, Morita Satoshi, Kodera Yasuhiro, Kobayashi Michiya, Shitara Kohei, Yamaguchi Kensei, Yoshikawa Takaki, Yoshida Kazuhiro, Yoshino Shigefumi and Sakamoto Jun-ichi. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). : BMC cancer. 20130617.